# The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes

> **NCT02890745** · PHASE2 · COMPLETED · sponsor: **Henrik Enghusen Poulsen** · enrollment: 31 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02890745
- **Lead sponsor:** Henrik Enghusen Poulsen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-22
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890745, "The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02890745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*